Wolfgang Poller

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3738912/publications.pdf

Version: 2024-02-01

102 papers	8,982 citations	50170 46 h-index	40881 93 g-index

105 all docs	105 docs citations	105 times ranked	9065 citing authors

#	Article	IF	Citations
1	Utility of Doppler Echocardiography and Tissue Doppler Imaging in the Estimation of Diastolic Function in Heart Failure With Normal Ejection Fraction. Circulation, 2007, 116, 637-647.	1.6	917
2	High Prevalence of Viral Genomes and Multiple Viral Infections in the Myocardium of Adults With â€œIdiopathicâ€•Left Ventricular Dysfunction. Circulation, 2005, 111, 887-893.	1.6	630
3	Viral Persistence in the Myocardium Is Associated With Progressive Cardiac Dysfunction. Circulation, 2005, 112, 1965-1970.	1.6	506
4	Cardiac Inflammation Contributes to Changes in the Extracellular Matrix in Patients With Heart Failure and Normal Ejection Fraction. Circulation: Heart Failure, 2011, 4, 44-52.	1.6	493
5	Interferon-Î² Treatment Eliminates Cardiotropic Viruses and Improves Left Ventricular Function in Patients With Myocardial Persistence of Viral Genomes and Left Ventricular Dysfunction. Circulation, 2003, 107, 2793-2798.	1.6	472
6	Role of Left Ventricular Stiffness in Heart Failure With Normal Ejection Fraction. Circulation, 2008, 117, 2051-2060.	1.6	403
7	Dilated Cardiomyopathy Is Associated With Significant Changes in Collagen Type I/III ratio. Circulation, 1999, 99, 2750-2756.	1.6	306
8	Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives. European Heart Journal, 2018, 39, 2704-2716.	1.0	300
9	Procoagulant Soluble Tissue Factor Is Released From Endothelial Cells in Response to Inflammatory Cytokines. Circulation Research, 2005, 96, 1233-1239.	2.0	253
10	Parvovirus B19 Infection Mimicking Acute Myocardial Infarction. Circulation, 2003, 108, 945-950.	1.6	235
11	Complication Rate of Right Ventricular Endomyocardial Biopsy via the Femoral Approach. Circulation, 2008, 118, 1722-1728.	1.6	223
12	Enteroviral RNA Replication in the Myocardium of Patients With Left Ventricular Dysfunction and Clinically Suspected Myocarditis. Circulation, 1999, 99, 889-895.	1.6	211
13	Human Coxsackie-Adenovirus Receptor Is Colocalized With Integrins Î± _v Î² ₃ and Î± _v Î² ₅ on the Cardiomyocyte Sarcolemma and Upregulated in Dilated Cardiomyopathy. Circulation, 2001, 104, 275-280.	1.6	190
14	Hematopoietic Deficiency of the Long Noncoding RNA MALAT1 Promotes Atherosclerosis and Plaque Inflammation. Circulation, 2019, 139, 1320-1334.	1.6	165
15	Cardiac fibroblasts support cardiac inflammation in heart failure. Basic Research in Cardiology, 2014, 109, 428.	2.5	128
16	Interferon-Beta Improves Survival in Enterovirus-Associated Cardiomyopathy. Journal of the American College of Cardiology, 2012, 60, 1295-1296.	1.2	120
17	Regulation of Human Endothelial Cell Focal Adhesion Sites and Migration by cGMP-dependent Protein Kinase I. Journal of Biological Chemistry, 2000, 275, 25723-25732.	1.6	115
18	The tight junction protein CAR regulates cardiac conduction and cellâ€“cell communication. Journal of Experimental Medicine, 2008, 205, 2369-2379.	4.2	106

#	Article	IF	Citations
19	Cardiac Deletion of the Coxsackievirus-Adenovirus Receptor Abolishes Coxsackievirus B3 Infection and Prevents Myocarditis In Vivo. Journal of the American College of Cardiology, 2009, 53, 1219-1226.	1.2	103
20	Collagen degradation in a murine myocarditis model: relevance of matrix metalloproteinase in association with inflammatory induction. Cardiovascular Research, 2002, 56, 235-247.	1.8	102
21	The molecular basis of Î±1-antichymotrypsin deficiency in a heterozygote with liver and lung disease. Journal of Hepatology, 1993, 18, 313-321.	1.8	97
22	Induction of Coxsackievirus-Adenovirusâ€“Receptor Expression During Myocardial Tissue Formation and Remodeling. Circulation, 2003, 107, 876-882.	1.6	91
23	Ubiquitin-Like Protein ISG15 (Interferon-Stimulated Gene of 15 kDa) in Host Defense Against Heart Failure in a Mouse Model of Virus-Induced Cardiomyopathy. Circulation, 2014, 130, 1589-1600.	1.6	91
24	Immune system-mediated atherosclerosis caused by deficiency of long non-coding RNAMALAT1in ApoEâ^'/â^'mice. Cardiovascular Research, 2019, 115, 302-314.	1.8	89
25	Adiponectin is a negative regulator of antigenâ€activated T cells. European Journal of Immunology, 2011, 41, 2323-2332.	1.6	87
26	Long noncoding RNA NEAT1 modulates immune cell functions and is suppressed in early onset myocardial infarction patients. Cardiovascular Research, 2019, 115, 1886-1906.	1.8	86
27	Reduced Degradation of the Chemokine MCP-3 by Matrix Metalloproteinase-2 Exacerbates Myocardial Inflammation in Experimental Viral Cardiomyopathy. Circulation, 2011, 124, 2082-2093.	1.6	81
28	Alterations in myocardial tissue factor expression and cellular localization in dilated cardiomyopathy. Journal of the American College of Cardiology, 2005, 45, 1081-1089.	1.2	78
29	Description of a local cardiac adiponectin system and its deregulation in dilated cardiomyopathy. European Heart Journal, 2008, 29, 1168-1180.	1.0	74
30	Left Ventricular Dysfunction Induced by Nonsevere Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 181-189.	2.5	74
31	Cardiac-targeted RNA interference mediated by an AAV9 vector improves cardiac function in coxsackievirus B3 cardiomyopathy. Journal of Molecular Medicine, 2008, 86, 987-997.	1.7	73
32	Carvedilol improves left ventricular function in murine coxsackievirus-induced acute myocarditis Association with reduced myocardial interleukin-1Î² and MMP-8 expression and a modulated immune response. European Journal of Heart Failure, 2005, 7, 444-452.	2.9	71
33	TRIF Is a Critical Survival Factor in Viral Cardiomyopathy. Journal of Immunology, 2011, 186, 2561-2570.	0.4	71
34	Long-term outcome of patients with virus-negative chronic myocarditis or inflammatory cardiomyopathy after immunosuppressive therapy. Clinical Research in Cardiology, 2016, 105, 1011-1020.	1.5	71
35	Chromosomally integrated human herpesvirus 6 in heart failure: prevalence and treatment. European Journal of Heart Failure, 2015, 17, 9-19.	2.9	70
36	Cdc2-Like Kinases and DNA Topoisomerase I Regulate Alternative Splicing of Tissue Factor in Human Endothelial Cells. Circulation Research, 2009, 104, 589-599.	2.0	69

#	Article	IF	Citations
37	Prevention of Cardiac Dysfunction in Acute Coxsackievirus B3 Cardiomyopathy by Inducible Expression of a Soluble Coxsackievirus-Adenovirus Receptor. Circulation, 2009, 120, 2358-2366.	1.6	67
38	Release of active and depot GDF-5 after adenovirus-mediated overexpression stimulates rabbit and human intervertebral disc cells. Journal of Molecular Medicine, 2004, 82, 126-134.	1.7	62
39	Protease-Activated Receptor-2 Regulates the Innate Immune Response to Viral Infection in a Coxsackievirus B3â€“Induced Myocarditis. Journal of the American College of Cardiology, 2013, 62, 1737-1745.	1.2	61
40	Adiponectin protects against Toll-like receptor 4-mediated cardiac inflammation and injury. Cardiovascular Research, 2013, 99, 422-431.	1.8	61
41	Preamplification techniques for real-time RT-PCR analyses of endomyocardial biopsies. BMC Molecular Biology, 2008, 9, 3.	3.0	60
42	From traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases. European Heart Journal, 2020, 41, 3884-3899.	1.0	58
43	Differential Recognition of Î±1-Antitrypsin-Elastase and Î±1-Antichymotrypsin-Cathepsin G Complexes by the Low Density Lipoprotein Receptor-related Protein. Journal of Biological Chemistry, 1995, 270, 2841-2845.	1.6	57
44	Matricellular Signaling Molecule CCN1 Attenuates Experimental Autoimmune Myocarditis by Acting as a Novel Immune Cell Migration Modulator. Circulation, 2010, 122, 2688-2698.	1.6	56
45	Long noncoding RNAMALAT1-derived mascRNA is involved in cardiovascular innate immunity. Journal of Molecular Cell Biology, 2016, 8, 178-181.	1.5	55
46	High leptin and resistin expression in chronic heart failure: adverse outcome in patients with dilated and inflammatory cardiomyopathy. European Journal of Heart Failure, 2012, 14, 1265-1275.	2.9	52
47	Increased risk of severe clinical course of COVID-19 in carriers of HLA-C*04:01. EClinicalMedicine, 2021, 40, 101099.	3.2	52
48	CCN1: a novel inflammation-regulated biphasic immune cell migration modulator. Cellular and Molecular Life Sciences, 2012, 69, 3101-3113.	2.4	49
49	Adiponectin expression in patients with inflammatory cardiomyopathy indicates favourable outcome and inflammation control. European Heart Journal, 2011, 32, 1134-1147.	1.0	46
50	Role of the Phosphatidylinositol 3-Kinase/Protein Kinase B Pathway in Regulating Alternative Splicing of Tissue Factor mRNA in Human Endothelial Cells. Circulation Journal, 2009, 73, 1746-1752.	0.7	43
51	Adiponectin modulates NKâ€cell function. European Journal of Immunology, 2013, 43, 1024-1033.	1.6	40
52	Cardiac-targeted delivery of regulatory RNA molecules and genes for the treatment of heart failure. Cardiovascular Research, 2010, 86, 353-364.	1.8	39
53	Familial Recurrent Myocarditis Triggered by Exercise in Patients With a Truncating Variant of the Desmoplakin Gene. Journal of the American Heart Association, 2020, 9, e015289.	1.6	39
54	Single-target RNA interference for the blockade of multiple interacting proinflammatory and profibrotic pathways in cardiac fibroblasts. Journal of Molecular and Cellular Cardiology, 2014, 66, 141-156.	0.9	38

#	Article	IF	Citations
55	Molecular characterisation of the defective Î±1-antitrypsin alleles PI MwÃ¼rzburg (Pro369Ser), Mheerlen (Pro369Leu), and Q0lisbon (Thr68Ile). European Journal of Human Genetics, 1999, 7, 321-331.	1.4	37
56	Cardiovascular RNA Interference Therapy. Circulation Research, 2013, 113, 588-602.	2.0	35
57	An improved Tet-On regulatable FasL-adenovirus vector system for lung cancer therapy. Journal of Molecular Medicine, 2006, 84, 215-225.	1.7	34
58	Tissue factor expression pattern in human non-small cell lung cancer tissues indicate increased blood thrombogenicity and tumor metastasis. Oncology Reports, 2008, , .	1.2	34
59	An isoform shift in the cardiac adenine nucleotide translocase expression alters the kinetic properties of the carrier in dilated cardiomyopathy. European Journal of Heart Failure, 2006, 8, 81-89.	2.9	33
60	Pharmacological and Biological Antiviral Therapeutics for Cardiac Coxsackievirus Infections. Molecules, 2011, 16, 8475-8503.	1.7	33
61	Immunomodulation by interleukin-4 suppresses matrix metalloproteinases and improves cardiac function in murine myocarditis. European Journal of Pharmacology, 2007, 554, 60-68.	1.7	32
62	Presence of perforin in endomyocardial biopsies of patients with inflammatory cardiomyopathy predicts poor outcome. European Journal of Heart Failure, 2014, 16, 1066-1072.	2.9	32
63	Differential Cardiac MicroRNA Expression Predicts the Clinical Course in Human Enterovirus Cardiomyopathy. Circulation: Heart Failure, 2015, 8, 605-618.	1.6	29
64	Inhibition of adenovirus infections by siRNA-mediated silencing of early and late adenoviral gene functions. Antiviral Research, 2010, 88, 86-94.	1.9	27
65	Protein modification with ISG15 blocks coxsackievirus pathology by antiviral and metabolic reprogramming. Science Advances, 2020, 6, eaay1109.	4.7	27
66	Vaccine protection against lethal homologous and heterologous challenge using recombinant AAV vectors expressing codon-optimized genes from pandemic swine origin influenza virus (SOIV). Vaccine, 2011, 29, 1690-1699.	1.7	25
67	Combination of soluble coxsackievirus-adenovirus receptor and anti-coxsackievirus siRNAs exerts synergistic antiviral activity against coxsackievirus B3. Antiviral Research, 2009, 83, 298-306.	1.9	24
68	Effects of the Cdc2-like kinase-family and DNA topoisomerase I on the alternative splicing of eNOS in TNF-Î±-stimulated human endothelial cells. Biological Chemistry, 2008, 389, 1333-8.	1.2	23
69	CAR-diologyâ€"a virus receptor in the healthy and diseased heart. Journal of Molecular Medicine, 2009, 87, 879-884.	1.7	23
70	Viral and nonviral factors causing nonspecific replication of tumor- and tissue-specific promoter-dependent oncolytic adenoviruses. Molecular Therapy, 2005, 11, 563-577.	3.7	22
71	Transactivation of human parvovirus B19 gene expression in endothelial cells by adenoviral helper functions. Virology, 2011, 411, 50-64.	1.1	22
72	The forkhead transcription factor Foxo3 negatively regulates natural killer cell function and viral clearance in myocarditis. European Heart Journal, 2018, 39, 876-887.	1.0	22

#	Article	IF	Citations
73	A Novel Artificial MicroRNA Expressing AAV Vector for Phospholamban Silencing in Cardiomyocytes Improves Ca2+ Uptake into the Sarcoplasmic Reticulum. PLoS ONE, 2014, 9, e92188.	1.1	19
74	High incidence of cardiac dysfunction and response to antiviral treatment in patients with chronic hepatitis C virus infection. Clinical Research in Cardiology, 2017, 106, 551-556.	1.5	19
75	Adenovirus-mediated overexpression and stimulation of the human angiotensin II type 2 receptor in porcine cardiac fibroblasts does not modulate proliferation, collagen I mRNA expression and ERK1/ERK2 activity, but inhibits protein tyrosine phosphatases. Journal of Molecular Medicine, 2001, 79, 510-521.	1.7	18
76	Combination of RNA Interference and Virus Receptor Trap Exerts Additive Antiviral Activity in Coxsackievirus B3-induced Myocarditis in Mice. Journal of Infectious Diseases, 2015, 211, 613-622.	1.9	17
77	Adiponectin attenuates profibrotic extracellular matrix remodeling following cardiac injury by up-regulating matrix metalloproteinase 9 expression in mice. Physiological Reports, 2017, 5, e13523.	0.7	17
78	Virome Sequencing in Patients With Myocarditis. Circulation: Heart Failure, 2020, 13, e007103.	1.6	16
79	Regulation of human factor IX expression using doxycycline-inducible gene expression system. Thrombosis and Haemostasis, 2003, 90, 398-405.	1.8	15
80	Effect of ionizing radiation on cellular procoagulability and co-ordinated gene alterations. Haematologica, 2007, 92, 1091-1098.	1.7	15
81	Impact of the Gut Microbiota on Atorvastatin Mediated Effects on Blood Lipids. Journal of Clinical Medicine, 2020, 9, 1596.	1.0	15
82	OUP accepted manuscript. Cardiovascular Research, 2021, 117, 2610-2623.	1.8	15
83	Immunohistological detection of Parvovirus B19 capsid proteins in endomyocardial biopsies from dilated cardiomyopathy patients. Medical Science Monitor, 2008, 14, CR333-338.	0.5	15
84	A bidirectional Tet-dependent promotor construct regulating the expression of E1A for tight control of oncolytic adenovirus replication. Journal of Biotechnology, 2007, 127, 560-574.	1.9	13
85	High Perforinâ€Positive Cardiac Cell Infiltration and Male Sex Predict Adverse Longâ€Term Mortality in Patients With Inflammatory Cardiomyopathy. Journal of the American Heart Association, 2017, 6, .	1.6	13
86	Identification of novel antigens contributing to autoimmunity in cardiovascular diseases. Clinical Immunology, 2016, 173, 64-75.	1.4	11
87	Cardiovascular Involvement in Chronic Hepatitis C Virus Infections â€“ Insight from Novel Antiviral Therapies. Journal of Clinical and Translational Hepatology, 2018, 6, 1-7.	0.7	11
88	Systemic overexpression of matricellular protein CCN1 exacerbates obliterative bronchiolitis in mouse tracheal allografts. Transplant International, 2015, 28, 1416-1425.	0.8	8
89	Missense Variant E1295K of Sodium Channel SCN5A Associated With Recurrent Ventricular Fibrillation and Myocardial Inflammation. JACC: Case Reports, 2022, 4, 280-286.	0.3	7
90	Interferon-Î² Suppresses Transcriptionally Active Parvovirus B19 Infection in Viral Cardiomyopathy: A Subgroup Analysis of the BICC-Trial. Viruses, 2022, 14, 444.	1.5	6

#	Article	IF	Citations
91	Nicotinamide Phosphoribosyltransferase/Preâ€“B-Cell Colony Enhancing Factor/Visfatin Plasma Levels and Clinical Outcome in Patients With Dilated Cardiomyopathy. Journal of Cardiac Failure, 2015, 21, 330-338.	0.7	5
92	Silencing Genes in the Heart. Methods in Molecular Biology, 2017, 1521, 17-39.	0.4	5
93	Severe heart failure in the setting of inflammatory cardiomyopathy with likely pathogenic titin variant. IJC Heart and Vasculature, 2022, 39, 100969.	0.6	4
94	Multimodality Imaging Reveals Divergent Responses of Left and Right Heart to Treatment in Cardiac Amyloidosis. JACC: Case Reports, 2019, 1, 360-366.	0.3	3
95	Molecular Genetic Analysis of NIDDM. Experimental and Clinical Endocrinology and Diabetes, 1993, 101, 58-68.	0.6	2
96	Viruses and Other Environmental Factors as Possible Sources of Phenotypic Heterogeneity in Familial Dilated Cardiomyopathy. Journal of the American College of Cardiology, 2006, 47, 689-690.	1.2	2
97	Endogenous migration modulators as parent compounds for the development of novel cardiovascular and antiâ€inflammatory drugs. British Journal of Pharmacology, 2012, 165, 2044-2058.	2.7	2
98	A novel Troponin I mutation associated with severe restrictive cardiomyopathy - A case report of a 27-year old woman with fatigue. European Heart Journal - Case Reports, 2022, 6, ytac053.	0.3	2
99	Eosinophilic granulomatosis with polyangiitis (EGPA) with low activity EBV replication during the COVID 19 pandemic. IJC Heart and Vasculature, 2022, 39, 100968.	0.6	2
100	Application of Molecular Genetics to the Study of Î²-Cell Function and Diabetes Mellitus. Experimental and Clinical Endocrinology and Diabetes, 1995, 103, 15-22.	0.6	1
101	Response to Letter Regarding Article, â€œRole of Left Ventricular Stiffness in Heart Failure With Normal Ejection Fractionâ€. Circulation, 2009, 119, .	1.6	1
102	The tight junction protein CAR regulates cardiac conduction and cellâ€“cell communication. Journal of Cell Biology, 2008, 182, i13-i13.	2.3	0